Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakob Dal

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Archives of Osteoporosis|December 9, 2022
Impaired postural control in diabetes-a predictor of falls?Nicklas Højgaard-Hessellund Rasmussen, Jakob Dal, Morten Hasselstrøm Jensen, et al.
Pituitary|March 14, 2025
Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literatureAstrid Thaarup Matthesen, Christian Rosendal, Emma H Christensen, et al.
Pituitary|August 1, 2024
Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngiomaErlend Gjersdal, Liva Bundgaard Larsen, Kåre Schmidt Ettrup, et al.
The Journal of Clinical Endocrinology and Metabolism|June 28, 2020
Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort StudyJakob Dal, Eigil H Nielsen, Ulla-Feldt Rasmussen, et al.
European Journal of Endocrinology|January 18, 2023
Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatmentMai C Arlien-Søborg, Michael Alle Madsen, Jakob Dal, et al.
European Journal of Endocrinology|December 17, 2025
Rising burden of PRL-PitNETs: patterns across tumour sizes and incidentalomasFrederik Østergaard Klit, Sara Faartoft Nørgård, Anna-Sofie Dam Berrett, et al.
European Journal of Endocrinology|October 11, 2017
Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre studyJakob Dal, Marianne Klose, Ansgar Heck, et al.
Acta Neuropsychiatrica|June 5, 2025
Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individualsEmma Elisabeth Skovby Petersen, Frederika Kiy, Ulrik Schiøler Kesmodel, et al.
The Journal of Clinical Endocrinology and Metabolism|July 29, 2016
Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog TreatmentJakob Dal, Katrine Lundby Høyer, Steen Bønløkke Pedersen, et al.
Pituitary|August 20, 2025
Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of lifeErlend Gjersdal, Frederik Østergaard Klit, Kåre Schmidt Ettrup, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Archives of Osteoporosis|December 9, 2022
Impaired postural control in diabetes-a predictor of falls?Nicklas Højgaard-Hessellund Rasmussen, Jakob Dal, Morten Hasselstrøm Jensen, et al.
Pituitary|March 14, 2025
Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literatureAstrid Thaarup Matthesen, Christian Rosendal, Emma H Christensen, et al.
Pituitary|August 1, 2024
Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngiomaErlend Gjersdal, Liva Bundgaard Larsen, Kåre Schmidt Ettrup, et al.
The Journal of Clinical Endocrinology and Metabolism|June 28, 2020
Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort StudyJakob Dal, Eigil H Nielsen, Ulla-Feldt Rasmussen, et al.
European Journal of Endocrinology|January 18, 2023
Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatmentMai C Arlien-Søborg, Michael Alle Madsen, Jakob Dal, et al.
European Journal of Endocrinology|December 17, 2025
Rising burden of PRL-PitNETs: patterns across tumour sizes and incidentalomasFrederik Østergaard Klit, Sara Faartoft Nørgård, Anna-Sofie Dam Berrett, et al.
European Journal of Endocrinology|October 11, 2017
Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre studyJakob Dal, Marianne Klose, Ansgar Heck, et al.
Acta Neuropsychiatrica|June 5, 2025
Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individualsEmma Elisabeth Skovby Petersen, Frederika Kiy, Ulrik Schiøler Kesmodel, et al.
The Journal of Clinical Endocrinology and Metabolism|July 29, 2016
Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog TreatmentJakob Dal, Katrine Lundby Høyer, Steen Bønløkke Pedersen, et al.
Pituitary|August 20, 2025
Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of lifeErlend Gjersdal, Frederik Østergaard Klit, Kåre Schmidt Ettrup, et al.
Pageof 6